Valsartan/sacubitril did not betray these expectations, showing improved outcomes (measured as mortality and hospitalization for HF) in HFrEF patients when compared with the ACE-I enalapril [301] (PARADIGM HF (NCT01035255). The gene discussed is ACE; the disease is hydrops fetalis.